Related Experiment Video
Updated: May 4, 2026
14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
8.9K
TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.
Jitka Malcikova1, Sarka Pavlova, Katerina Stano Kozubik
1Central European Institute of Technology, Center of Molecular Medicine, and Faculty of Medicine, Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic.
Human Mutation
|January 14, 2014
Summary
TP53 gene mutations and deletions significantly impact survival and treatment outcomes in chronic lymphocytic leukemia (CLL). Analyzing these TP53 defects is crucial for accurate prognostication and guiding therapy decisions in CLL patients.
Area of Science:
- Oncology
- Genetics
- Hematology
Background:
- TP53 mutations are infrequent in leukemia but strongly linked to poor prognosis and reduced therapy response.
- TP53 gene defects are critical for disease prognostication in chronic lymphocytic leukemia (CLL).
Purpose of the Study:
- To detail the biological and clinical effects of TP53 dysfunction in CLL.
- To outline methodical approaches for TP53 analysis in CLL.
- To highlight the significance of detecting both TP53 mutations and deletions for patient outcomes.
Main Methods:
- TP53 locus deletions (17p) are routinely detected using interphase fluorescence in situ hybridization (I-FISH).
- TP53 mutations are analyzed using various methods, with next-generation sequencing (NGS) emerging as a standard option.
- Ultradeep NGS enables detection of TP53 mutations in minor subclones (<1%).
Main Results:
- Monoallelic TP53 mutations, similar to deletions, confer a negative prognostic impact in CLL.
- Next-generation sequencing (NGS) offers a convenient method for routine TP53 mutation analysis.
- The clinical significance of minor TP53-defective subclones is under investigation but poses a therapeutic selection risk.
Conclusions:
- Comprehensive TP53 analysis, including mutations and deletions, is essential for CLL prognostication.
- Next-generation sequencing (NGS) is a valuable tool for detecting TP53 alterations in CLL.
- Further research is needed to understand the prognostic implications of minor TP53-defective subclones in CLL therapy.
